SoCalBio

May 11, 2023

LOS ANGELES–(BUSINESS WIRE)—- $CDXC #earnings–ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the first quarter of 2023. First Quarter 2023 and Recent Highlights Total net sales were $22.6 million, up 31% from the prior year quarter, with $17.6 million from Tru Niagen®. Strong gross margin of 59.9% and a $2.8 million reduction in operating expenses, reflecting financial discipline. Selling and marketing expense as a percentage of net sales was 34.9% versus 47.7%, an improvement of 1,280 bas

Go to Source

Author: